Literature DB >> 10323702

Breast cancer found at the time of breast reduction.

C L Tang1, M H Brown, R Levine, M Sloan, N Chong, E Holowaty.   

Abstract

In a recent study involving 27,500 women who had breast reduction surgery in Ontario, Canada, 17 women who were diagnosed as having breast cancer at the time of their breast reduction surgery were identified. The aims of this study were to (1) describe a population-based series of patients who had breast cancer diagnosed at the time of breast reduction, (2) describe the treatment of these cancers, and (3) compare their survival rate with survival in patients in the general population who had breast cancer. Information about these women, their treatment, and outcome was extracted from hospital records, pathology reports, and reports from regional cancer centers. The chance of finding an invasive breast cancer at the time of breast reduction was 0.06 percent, which is lower than what has been reported previously. Sixty-seven percent of these women were treated with total mastectomy. In the remaining 33 percent, who were treated with partial mastectomy, the entire tumor was removed at the time of breast reduction. Fifty percent of the women were treated with radiation, and 25 percent were treated with chemotherapy or hormonal therapy. Compared with women in the general population of Ontario who have breast cancer, women whose breast cancer is discovered during breast reduction surgery are more likely to be treated with complete mastectomy and less likely to be treated with radiotherapy or chemotherapy. Seventy-one percent of the breast reduction group were axillary node-negative at diagnosis, compared with 58 percent in the general population of women with breast cancer. Survival from breast cancer in women diagnosed at the time of breast reduction (88 percent, 5-year survival) was better than survival from breast cancer in the general population (77 percent). These findings suggest that cancers found in women at the time of breast reduction are less advanced, possibly because they are diagnosed at an earlier stage.

Entities:  

Mesh:

Year:  1999        PMID: 10323702     DOI: 10.1097/00006534-199905060-00016

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  6 in total

1.  Pathology Evaluation of Reduction Mammaplasty Specimens and Subsequent Diagnosis of Malignant Breast Disease: A Claims-Based Analysis.

Authors:  Erika D Sears; Yu-Ting Lu; Ting-Ting Chung; Adeyiza O Momoh; Kevin C Chung
Journal:  World J Surg       Date:  2019-06       Impact factor: 3.352

2.  Breast reduction surgery in the UK and Ireland - current trends.

Authors:  O C Iwuagwu; A J Platt; P J Drew
Journal:  Ann R Coll Surg Engl       Date:  2006-10       Impact factor: 1.891

3.  Incidental Findings in Reduction Mammoplasty Specimens in Patients with No Prior History of Breast Cancer. An Analysis of 783 Specimens.

Authors:  Pedro Luiz Serrano Usón Junior; Donato Callegaro Filho; Diogo Diniz Gomes Bugano; Felipe Correa Geyer; Marcus Vinicius de Nigro Corpa; Paulo David Scatena Gonçalves; Sergio Daniel Simon; Rafael Aliosha Kaliks
Journal:  Pathol Oncol Res       Date:  2017-04-08       Impact factor: 3.201

4.  Pathological Evaluation of Breast Specimens in Transgender Chest Masculinization: Incidental Findings and Effect of Prior Chest Binding and Androgen Therapy in 74 Consecutive Patients.

Authors:  Jerette J Schultz; Alexandra I Naides; Di Bai; Nikita O Shulzhenko; Jonathan D Keith
Journal:  Transgend Health       Date:  2021-12-02

5.  Histopathological evaluation of reduction mammaplasty specimens to detect occult breast cancer: a report from southern iran.

Authors:  Mohammad Hossain Rajabian; Perikala Vijayananda Kumar
Journal:  World J Plast Surg       Date:  2012-07

6.  Breast lesions in reduction mammaplasty specimens: a histopathological pattern in 534 patients.

Authors:  M Tadler; G Vlastos; M-F Pelte; J-C Tille; C Bouchardy; M Usel; B Pittet-Cuénod; A Modarressi
Journal:  Br J Cancer       Date:  2013-11-14       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.